Drug intelligence / Profile preview

KI-1122

Development stage: Preclinical
Lead developer: Kuhnil Pharmaceutical
Modality: Small Molecules

Overview

KI-1122 is a preclinical-stage drug candidate being developed by Kuhnil Pharmaceutical Co., Ltd., a South Korean pharmaceutical company, for the treatment of hyperlipidemia. As of the current development status, the compound is in the research phase of preclinical development. Specific details regarding the drug's active ingredient, biological target, and modality (such as whether it is a small molecule or a biologic) have not been publicly disclosed by the developer. Kuhnil Pharma, established in 1969, focuses on the development of therapeutics for cardiovascular, metabolic, and central nervous system diseases.

Brand names: Atomega
Other names: atorvastatin + omega-3-acid ethyl estersatorvastatin/omega-3-acid ethyl esters

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on KI-1122.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KI-1122.

Explore the full profile